Lack of Relationship Between Purine Biosynthesis and Vancomycin Resistance in Staphylococcus Aureus: a Cautionary Tale for Microarray Interpretation
Overview
Affiliations
Previous microarray data (E. Mongodin, J. Finan, M. W. Climo, A. Rosato, S. Gill, and G. L. Archer, J. Bacteriol. 185:4638-4643, 2003) noted an association in two vancomycin-intermediate Staphylococcus aureus (VISA) strains between high-level, passage-induced vancomycin resistance, a marked increase in the transcription of purine biosynthetic genes, and mutation of the putative purine regulator purR. Initial studies to report on the possible association between vancomycin resistance and alterations in purine metabolism in one of these strains (VP-32) confirmed, by Western analysis, an increase in the translation of PurH and PurM, two purine pathway enzymes. In addition, PurR was identified, by knockout and complementation in a vancomycin-susceptible strain, as a repressor of the purine biosynthetic operon in S. aureus, and the PurR missense mutation was shown to inactivate the repressor. However, despite the apparent relationship between increased purine biosynthesis and increased vancomycin resistance in VP-32, neither the addition of exogenous purines to a defined growth medium nor the truncation or inactivation of purR improved the growth of vancomycin-susceptible S. aureus in the presence of vancomycin. Furthermore, the passage of additional vancomycin-susceptible and VISA strains to high-level vancomycin resistance occurred without changes in cellular purine metabolism or mutation of purR despite the development of thickened cell walls in passaged strains. Thus, we could confirm neither a role for altered purine metabolism in the development of vancomycin resistance nor its requirement for the maintenance of a thickened cell wall. The failure of biochemical and physiological studies to support the association between transcription and phenotype initially found in careful microarray studies emphasizes the importance of follow-up investigations to confirm microarray observations.
Aguglia E, Chines E, Stefani S, Cafiso V Antibiotics (Basel). 2023; 12(4).
PMID: 37107145 PMC: 10135003. DOI: 10.3390/antibiotics12040783.
Insights Into the Impact of Small RNA SprC on the Metabolism and Virulence of .
Zhou J, Zhao H, Yang H, He C, Shu W, Cui Z Front Cell Infect Microbiol. 2022; 12:746746.
PMID: 35281456 PMC: 8905650. DOI: 10.3389/fcimb.2022.746746.
(Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate .
Lamichhane-Khadka R, Dulal S, Cuaron J, Pfeltz R, Gupta S, Wilkinson B Antibiotics (Basel). 2021; 10(5).
PMID: 34069103 PMC: 8170892. DOI: 10.3390/antibiotics10050583.
Resistance to Arg-Teixobactin Occurs Slowly and Is Costly.
Lloyd D, Schofield B, Goddard M, Taylor E Antimicrob Agents Chemother. 2020; 65(1).
PMID: 33046494 PMC: 7927836. DOI: 10.1128/AAC.01152-20.
Chen C, Huang Y, Shie S Front Microbiol. 2020; 11:1414.
PMID: 32774327 PMC: 7381330. DOI: 10.3389/fmicb.2020.01414.